Evaluation of the usefullness of perioperative administration of tiotropium and indacaterol in lung cancer patients with COPD.

Evaluation of the usefullness of perioperative administration of tiotropium and indacaterol in lung cancer patients with COPD. - PALC study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010948

Enrollment

Registered

2013-06-13

Start date

2013-06-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease

Interventions

18 microgram once daily Tiotropium 150 microgram once daily Indacaterol+ 18 microgram once daily Tiotropium

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Non-small cell lung cancer stage1~3. 2) Partial lung resection or lobectomy. 3) Patients with the clinical diagnosis of COPD and with a FEV1/FVC of < 70% after inhalation of beta 2 agonist. 4) Patients with GOLD stage 1~3. 5) Patients aged >40 years old. 6) Patients that provided consent/permission

Exclusion criteria

Exclusion criteria: 1) Patients with large atelectasis. 2) Patients with clear evidence of underlying bronchial asthma. 3) Patients that had airway infection or COPD exacerbation within the past 3 months after administration of the drug on trial. 4) Patients that cannot stop smoking at the start of the study. 5) Patients with a history of hypersensitivity to Tiotropium or Indacaterol. 6) Patients with benign prostatic hyperplasia. 7) Patients with glaucoma. 8) Pregnant or breast feeding patients. 9) Patients considered as ineligible by the panel of investigators.

Design outcomes

Primary

Measure	Time frame
forced expiratory volume in 1 second	—

Countries

Japan

Contacts

Public ContactTetsu Kobayashi

Mie University Graduate School of Medicine Dep. of Pulmonary and Critical Care Medicine

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026